SCHEMBL11944490

SCHEMBL11944490

CC(C)S(=O)(=O)N1CCN(c2cnn(-c3cc(F)cc(F)c3)c(=O)c2OCC(C)(C)c2ccc(Cl)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.41
POLB P06746 1/20 0.41
CYP2C19 P33261 1/20 0.41
PPARG P37231 1/20 0.41
NCOA2 Q15596 1/20 0.41
NCOA1 Q15788 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.38
DCTPP1 Q9H773 1/20 0.37
LMNA P02545 2/20 0.37
CYP17A1 P05093 5/20 0.35
CYP21A2 P08686 5/20 0.35
TSHR P16473 1/20 0.35
MCHR1 Q99705 2/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
HSD11B1 P28845 1/20 0.34
NPBWR1 P48145 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11944365 0.91 ALDH1A1 (0.46) CYP3A4POLBCYP2C19PPARGNCOA2
SCHEMBL11944382 0.89 CYP3A4 (0.41) CYP3A4POLBCYP2C19PPARGNCOA2
SCHEMBL11944499 0.89 ALDH1A1 (0.43) CYP3A4POLBCYP2C19PPARGNCOA2
SCHEMBL17058071 0.85 CYP3A4 (0.35) CYP3A4POLBCYP2C19PPARGNCOA2
SCHEMBL17058107 0.85 POLB (0.36) CYP3A4POLBCYP2C19PPARGNCOA2
SCHEMBL11944343 0.83 POLB (0.39) CYP3A4POLBCYP2C19PPARGNCOA2
SCHEMBL11944221 0.82 NPSR1 (0.37) CYP3A4POLBCYP2C19PPARGNCOA2
SCHEMBL11945418 0.82 POLB (0.49) CYP3A4POLBCYP2C19PPARGNCOA2
SCHEMBL11944133 0.81 NPSR1 (0.37) CYP3A4POLBCYP2C19PPARGNCOA2
SCHEMBL11945408 0.81 NPSR1 (0.43) CYP3A4POLBCYP2C19PPARGNCOA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137179-B1 PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS MERCK SHARP & DOHME (US) 2015-09-02 EP disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA CYP3A4 281/4885POLB 1088/4885CYP2C19 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.